Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

• click to rate

  Posted by Two Blokes Jul 18 - Filed in Stock - 3 views
  
  Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revised downward. The impending approval of a rival therapy in the advanced melanoma space - Replimmune's RP1 - is another cause for concern.